These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. Virgili G; Parravano M; Menchini F; Brunetti M Cochrane Database Syst Rev; 2012 Dec; 12():CD007419. PubMed ID: 23235642 [TBL] [Abstract][Full Text] [Related]
10. Effects of lipid-lowering agents on diabetic retinopathy: a Meta-analysis and systematic review. Shi R; Zhao L; Wang F; Liu F; Chen Z; Li R; Liu Y; Lin R Int J Ophthalmol; 2018; 11(2):287-295. PubMed ID: 29487821 [TBL] [Abstract][Full Text] [Related]
11. Management of diabetic retinopathy: a systematic review. Mohamed Q; Gillies MC; Wong TY JAMA; 2007 Aug; 298(8):902-16. PubMed ID: 17712074 [TBL] [Abstract][Full Text] [Related]
12. Pan-retinal photocoagulation and other forms of laser treatment and drug therapies for non-proliferative diabetic retinopathy: systematic review and economic evaluation. Royle P; Mistry H; Auguste P; Shyangdan D; Freeman K; Lois N; Waugh N Health Technol Assess; 2015 Jul; 19(51):v-xxviii, 1-247. PubMed ID: 26173799 [TBL] [Abstract][Full Text] [Related]
13. Conjunctival autograft for pterygium. Clearfield E; Muthappan V; Wang X; Kuo IC Cochrane Database Syst Rev; 2016 Feb; 2(2):CD011349. PubMed ID: 26867004 [TBL] [Abstract][Full Text] [Related]
14. Optical coherence tomography (OCT) for detection of macular oedema in patients with diabetic retinopathy. Virgili G; Menchini F; Murro V; Peluso E; Rosa F; Casazza G Cochrane Database Syst Rev; 2011 Jul; (7):CD008081. PubMed ID: 21735421 [TBL] [Abstract][Full Text] [Related]
15. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. Parravano M; Menchini F; Virgili G Cochrane Database Syst Rev; 2009 Oct; (4):CD007419. PubMed ID: 19821414 [TBL] [Abstract][Full Text] [Related]
16. Head-to-head comparison of fibrates versus statins for elevation of circulating adiponectin concentrations: a systematic review and meta-analysis. Sahebkar A Metabolism; 2013 Dec; 62(12):1876-85. PubMed ID: 24095632 [TBL] [Abstract][Full Text] [Related]
17. Lipids, hyperreflective crystalline deposits and diabetic retinopathy: potential systemic and retinal-specific effect of lipid-lowering therapies. Jenkins AJ; Grant MB; Busik JV Diabetologia; 2022 Apr; 65(4):587-603. PubMed ID: 35149880 [TBL] [Abstract][Full Text] [Related]
18. Neuroprotection for treatment of glaucoma in adults. Sena DF; Lindsley K Cochrane Database Syst Rev; 2017 Jan; 1(1):CD006539. PubMed ID: 28122126 [TBL] [Abstract][Full Text] [Related]
19. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Perkovic V; Hegbrant J; Strippoli GF Cochrane Database Syst Rev; 2014 May; (5):CD007784. PubMed ID: 24880031 [TBL] [Abstract][Full Text] [Related]
20. Potential utility of statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in diabetic retinopathy. Yamagishi S; Nakamura K; Matsui T; Sato T; Takeuchi M Med Hypotheses; 2006; 66(5):1019-21. PubMed ID: 16188392 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]